Compulsory Licence for Diabetes Drug : Legality of Lee Pharma's Application

This article examines the legality of the Indian pharmaceutical company Lee Pharma's application for compulsory licence for Saxagliptin (Onglyza and Kombiglyze), an anti-diabetes drug, the patent for which is held by the Swedish multinational company AstraZeneca. What are the merits of the prima facie view taken by the controller of patents and the possibility of Lee Pharma getting the licence under the Indian patents law?

MoreLess

Year of publication:	2017
Authors:	Pandey, B N
Other Persons:	Saha, Prabhat Kumar (contributor)
Publisher:	[2017]: [S.l.] : SSRN
Subject:	Arzneimittel \| Pharmaceuticals \| Pharmaindustrie \| Pharmaceutical industry \| Diabetes \| Pharmakologie \| Pharmacology \| Lizenz \| Licence \| Patent

freely available

Full text |

More access options

Check Google Scholar

In German libraries (KVK)

I need help

Extent:	1 Online-Ressource (3 p)
Type of publication:	Book / Working Paper
Language:	English
Notes:	In: Economic & Political Weekly, Vol LI, No 2, 2016 Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments January 9, 2016 erstellt
Source:	ECONIS - Online Catalogue of the ZBW

Persistent link: https://www.econbiz.de/10012965056